Clinical Trial Update: Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 trial of Namodenoson for advanced hepatocellular carcinoma in patients with Child-Pugh B7 cirrhosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatocellular Carcinoma

Drugs mentioned

• Namodenoson (Namodenoson)

Snippet

Sponsor: Can-Fite BioPharma | Conditions: Hepatocellular Carcinoma, Cirrhosis | Phase 3 | Status: RECRUITING